Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
TEAR's Cash to Debt is ranked higher than
90% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.91 vs. TEAR: No Debt )
TEAR' s 10-Year Cash to Debt Range
Min: 0.09   Max: No Debt
Current: No Debt

Equity to Asset 0.87
TEAR's Equity to Asset is ranked higher than
92% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. TEAR: 0.87 )
TEAR' s 10-Year Equity to Asset Range
Min: -1.1   Max: 0.96
Current: 0.87

-1.1
0.96
Interest Coverage No Debt
TEAR's Interest Coverage is ranked higher than
76% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 127.94 vs. TEAR: No Debt )
TEAR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 6
Z-Score: -2.87
M-Score: -2.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -118.40
TEAR's Operating margin (%) is ranked higher than
54% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. TEAR: -118.40 )
TEAR' s 10-Year Operating margin (%) Range
Min: -48893.1   Max: -121.37
Current: -118.4

-48893.1
-121.37
Net-margin (%) -108.59
TEAR's Net-margin (%) is ranked higher than
55% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.29 vs. TEAR: -108.59 )
TEAR' s 10-Year Net-margin (%) Range
Min: -75902.17   Max: -197.95
Current: -108.59

-75902.17
-197.95
ROE (%) -59.25
TEAR's ROE (%) is ranked higher than
54% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. TEAR: -59.25 )
TEAR' s 10-Year ROE (%) Range
Min: -214.14   Max: -15.27
Current: -59.25

-214.14
-15.27
ROA (%) -46.59
TEAR's ROA (%) is ranked higher than
54% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.28 vs. TEAR: -46.59 )
TEAR' s 10-Year ROA (%) Range
Min: -715.24   Max: -14.38
Current: -46.59

-715.24
-14.38
ROC (Joel Greenblatt) (%) -615.72
TEAR's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.50 vs. TEAR: -615.72 )
TEAR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8269.06   Max: -875.78
Current: -615.72

-8269.06
-875.78
Revenue Growth (%) 58.70
TEAR's Revenue Growth (%) is ranked higher than
99% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. TEAR: 58.70 )
TEAR' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 58.7
Current: 58.7

0
58.7
EBITDA Growth (%) 36.00
TEAR's EBITDA Growth (%) is ranked higher than
95% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. TEAR: 36.00 )
TEAR' s 10-Year EBITDA Growth (%) Range
Min: -77.8   Max: 97.5
Current: 36

-77.8
97.5
EPS Growth (%) 26.00
TEAR's EPS Growth (%) is ranked higher than
91% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. TEAR: 26.00 )
TEAR' s 10-Year EPS Growth (%) Range
Min: -78.6   Max: 71.6
Current: 26

-78.6
71.6
» TEAR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

TEAR Guru Trades in Q3 2013

Jim Simons Sold Out
Chuck Royce 6,300 sh (-36.36%)
» More
Q4 2013

TEAR Guru Trades in Q4 2013

Chuck Royce 488,229 sh (+7649.67%)
» More
Q1 2014

TEAR Guru Trades in Q1 2014

Chuck Royce 1,046,731 sh (+114.39%)
» More
Q2 2014

TEAR Guru Trades in Q2 2014

Chuck Royce 100,000 sh (-90.45%)
» More
» Details

Insider Trades

Latest Guru Trades with TEAR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.27
TEAR's P/B is ranked higher than
75% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.12 vs. TEAR: 3.27 )
TEAR' s 10-Year P/B Range
Min: 0.18   Max: 63.48
Current: 3.27

0.18
63.48
P/S 6.31
TEAR's P/S is ranked higher than
61% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.97 vs. TEAR: 6.31 )
TEAR' s 10-Year P/S Range
Min: 5.5   Max: 406.25
Current: 6.31

5.5
406.25
EV-to-EBIT -4.17
TEAR's EV-to-EBIT is ranked lower than
51% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 168.09 vs. TEAR: -4.17 )
TEAR' s 10-Year EV-to-EBIT Range
Min: 0.1   Max: 0.4
Current: -4.17

0.1
0.4
Current Ratio 5.99
TEAR's Current Ratio is ranked higher than
88% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. TEAR: 5.99 )
TEAR' s 10-Year Current Ratio Range
Min: 0.19   Max: 20.62
Current: 5.99

0.19
20.62
Quick Ratio 5.55
TEAR's Quick Ratio is ranked higher than
89% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. TEAR: 5.55 )
TEAR' s 10-Year Quick Ratio Range
Min: 0.14   Max: 19.15
Current: 5.55

0.14
19.15

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.58
TEAR's Price/Net Cash is ranked higher than
93% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TEAR: 5.58 )
TEAR' s 10-Year Price/Net Cash Range
Min: 3.08   Max: 22.78
Current: 5.58

3.08
22.78
Price/Net Current Asset Value 4.79
TEAR's Price/Net Current Asset Value is ranked higher than
92% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. TEAR: 4.79 )
TEAR' s 10-Year Price/Net Current Asset Value Range
Min: 3.02   Max: 275
Current: 4.79

3.02
275
Price/Tangible Book 3.73
TEAR's Price/Tangible Book is ranked higher than
79% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.18 vs. TEAR: 3.73 )
TEAR' s 10-Year Price/Tangible Book Range
Min: 2.93   Max: 179.35
Current: 3.73

2.93
179.35
Price/Median PS Value 0.18
TEAR's Price/Median PS Value is ranked higher than
99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. TEAR: 0.18 )
TEAR' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 9.28
Current: 0.18

0.16
9.28
Earnings Yield (Greenblatt) 4952.80
TEAR's Earnings Yield (Greenblatt) is ranked higher than
99% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. TEAR: 4952.80 )
TEAR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 256.6   Max: 5011.7
Current: 4952.8

256.6
5011.7
Forward Rate of Return (Yacktman) 2.30
TEAR's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.72 vs. TEAR: 2.30 )
TEAR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.5   Max: 3.3
Current: 2.3

2.5
3.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:TLB.Canada, OCV1.Germany
TearLab Corpoartion was incorporated as OccuLogix, Inc. in Delaware in 2002. The Company is an in-vitro diagnostic company based in San Diego, California. The Company is commercializing a proprietary tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for highly sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company's first product measures tear film osmolarity for the diagnosis of Dry Eye Disease, or DED. TearLab Research, Inc. its wholly-owned subsidiary, develops technologies to enable eye care practitioners to test a wide range of biomarkers (chemistries, metabolites (i.e. glucose), genes and proteins) at the point-of-care. Commercializing that tear testing platform is now the focus of its business. The Company's first product, the TearLab Osmolarity System, enables the rapid measurement of tear osmolarity in the doctor's office. Osmolarity is a quantitative and highly specific biomarker that has been shown to assist in the diagnosis and disease management of DED. There are estimated to be between 20 million and 40 million DED patients in the United States, and less than 5% of those patients are currently diagnosed and treated. The innovation of the TearLab Osmolarity System is its ability to precisely and rapidly measure osmolarity in nanoliter volumes of tear samples, using a highly efficient and novel tear collection system at the point of care. The TearLab Osmolarity System consists of the following three components: the TearLab disposable, which is a single-use microfluidic microchip; the TearLab Pen, which is a hand-held device that interfaces with the TearLab disposable; and the TearLab Reader, which is a small desktop unit that allows for the docking of the TearLab Pen and provides a quantitative reading for the operator. Government authorities in the United States and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising, distribution and marketing of its product, which is a medical device.
» More Articles for TEAR

Headlines

Articles On GuruFocus.com
comment on TEAR Mar 06 2013 

More From Other Websites
TearLab to Participate in BTIG's Inaugural Emerging Technologies in Healthcare Diagnostics Symposium Sep 25 2014
Study Demonstrates Hyperosmolarity of the Ocular Surface May Impact Cataract Surgery Planning Sep 15 2014
TearLab to Participate in Craig-Hallum's 5th Annual Alpha Select Conference Sep 11 2014
TearLab Reports Interim Results From Multi-Center DED Prevalence Study in the UK Sep 04 2014
TEARLAB CORP Financials Aug 15 2014
TearLab to Host Analyst and Investor Day Aug 14 2014
TearLab to Participate in the Canaccord Genuity 34th Annual Growth Conference Aug 11 2014
TEARLAB CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 07 2014
TearLab Corporation Reports Q2-14 Financial Results and Adjusts 2014 Revenue Guidance Aug 07 2014
TearLab Corporation to Release Q2 2014 Financial Results on August 7, 2014 Jul 16 2014
TEARLAB CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Jul 16 2014
Manoj Venkiteshwar Joins TearLab as VP of Medical Affairs Jul 14 2014
TEARLAB CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to... Jun 13 2014
3 Stocks Trading at 52-Week Lows — Is This the Bottom? May 19 2014
TearLab price target lowered to $10 from $15 at Canaccord May 09 2014
TearLab Corporation's (TEAR) CEO Elias Vamvakas on Q1 2014 Results - Earnings Call Transcript May 08 2014
TearLab reports Q1 EPS (17c), consensus (14c) May 08 2014
TearLab (TEAR) Enters Oversold Territory May 01 2014
TEARLAB CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Apr 21 2014
TEARLAB CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or... Mar 17 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK